Overview

Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

Status:
Withdrawn
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
This study will compare response to treatment of Eosinophilic Esophagitis with montelukast vs standard therapy fluticasone. Investigators hypothesize that montelukast is equally effective in treating symptoms and histology of EoE when compared to fluticasone. The study will be conducted at multiple sites with Medical College of Wisconsin as the coordinating site. After identification and recruitment all patients will be randomized (provider blinded) to one of two medications: montelukast 10mg po qday vs fluticasone 440mcg po bid. Patients will also complete a pretreatment, 6 week therapy and 12 week therapy questionaire. They will then undergo a repeat endoscopy to evaluate endoscopic and histologic response.
Phase:
Phase 3
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Fluticasone
Montelukast